GlaxoSmithKline (GSK) is expected to have two of the top-five best-selling drugs in the respiratory market in 2018, maintaining its strong portfolio of products in this market.

The top-selling drug in 2018 is expected to be a combination therapy for asthma, chronic obstructive pulmonary disorders (COPD), emphysema and bronchitis.

This therapy is a combination of Seretide and Advair, which is forecast to reach sales of $3.4bn in 2018, despite its patent expiry in 2010 and a significant fall in sales from 2017.

Mitigating the loss in revenue

Relvar plus Breo Ellipta, a combination therapy for asthma, COPD, chronic bronchitis and emphysema, is forecast to reach sales of $1.9bn in 2018, and, unlike GSK’s other top-selling drugs, it is forecast to register sales growth in the next few years.

Nucala is a monoclonal antibody that is used for the treatment of asthma and COPD and was first approved in 2015.

It is one of the first and most recent antibodies to enter treatment for asthma and COPD and has shown strong signs of developing into a blockbuster therapy due to its ability to treat severe asthma, which is otherwise untreatable and causes a severe reduction in patients’ quality of life.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.